Redeye: BONESUPPORT - Positively reviewed long-term outlooks

2022-10-25 08:50:00

Redeye raises its fair value range following a review of BONESUPPORT’s long-term potential. Our updated and lengthened financial forecast better reflects the company’s strong value proposition, which we believe positions CERAMENT well for becoming a paradigm shift driver towards locally eluting antibiotic synthetic bone grafts in bone defect treatment.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

MFN